Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
复制标题
通过定量逆转录酶-聚合酶链反应监测 AML-M2 中 t(8; 21) 中的 AML1-MTG8 转录物的微小残留病。
DOI：
10.1182/blood.v88.10.3704.bloodjournal88103704
复制
发表时间：
1996
期刊：
影响因子：
20.3
通讯作者：
Liu Yin
中科院分区：
文献类型：
--
作者：
Khalid Tobal;John;Liu Yin
我们已经开发了一种定量逆转录-聚合酶链反应方法，用于定量AML-M2和t（8;21）患者在疾病不同阶段的AML 1-MTG 8转录本。使用这种方法，我们测试了13名患者的连续样本以监测微小残留疾病，并能够显示两名患者在临床复发前2个月和4个月的AML 1-MTG 8转录水平显着增加。在5名患者中，在就诊时和随后的缓解期进行了检测，我们检测到随着治疗的进展，AML 1-MTG 8转录物的水平显著降低。长期缓解的患者其疾病水平高达1 × 10（3）AML 1-MTG 8分子/微克RNA。两名患者在血液学复发前2个月和4个月检测显示0.71 × 10（5）分子/微克RNA的水平，在复发期间该水平进一步增加，分别为0.71 × 10（7）和2.27 × 10（5）分子/微克RNA。我们的研究结果表明，通过竞争性聚合酶链反应定量AML 1-MTG 8转录物在预测t（8;21）AML早期复发中是有价值的。识别有风险的患者可能允许修改治疗，以包括额外或替代治疗，如骨髓移植。
We have developed a quantitative reverse transcriptase-polymerase chain reaction method for the quantitation of AML1-MTG8 transcripts in patients with AML-M2 and t(8;21) in different phases of the disease. Using this method, we have tested sequential samples from 13 patients to monitor minimal residual disease and were able to show a significant increase in AML1-MTG8 transcripts level in two patients 2 and 4 months before clinical relapse. In five patients tested at presentation and then sequentially at remission, we detected a marked decrease in the level of AML1-MTG8 transcripts as the treatment progressed. Patients in long-term remission of their disease had a level of up to 1 x 10(3) AML1-MTG8 molecules/microgram RNA. Two patients tested 2 and 4 months before hematologic relapse showed a level of 0.71 x 10(5) molecules/microgram RNA and this level increased further during relapse to 0.71 x 10(7) and 2.27 x 10(5) molecules/microgram RNA, respectively. Our results show that quantitation of AML1-MTG8 transcripts by competitive polymerase chain reaction is valuable in predicting early relapse in AML with t(8;21). Identification of at-risk patients may allow treatment to be modified to include additional or alternative therapy such as bone marrow transplantation.